The Study of Genes Localization for Female Pelvic Floor Dysfunction

The Study of Susceptibility Genes Localization for Female Pelvic Floor Dysfunction

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02166528

Acronym

PFD POP UI

Enrollment

200

Registered

2014-06-18

Start date

2013-11-30

Completion date

2017-10-31

Last updated

2014-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Pelvic Floor Dysfunction

Keywords

female pelvic floor dysfunction, pelvic organ prolaps, urinary incontinence, massively parallel sequencing

Brief summary

Female pelvic floor dysfunction (FPD) is due to defects in the pelvic support structures, degradation, damage or dysfunction. The main problem of which is pelvic organ prolapse(POP), urinary incontinence(UI) and genital tract injury. Although it does not pose a serious threat to life, but affect the patient's quality of life seriously in the physical, psychological, social behavior and other aspects. With the growing aging population, the incidence rate has gradually increased, and increasing demands for people's quality of life simultaneously, more and more attention was raised to PFD as common chronic diseases. In recent years, the basic research, epidemiology, prevention, diagnosis and treatment of PFD have made great progress, especially in developing gynecological urology theory and reconstructive pelvic surgery. But overall the basic research of PFD is lagging behind, especially susceptibility gene localization and functional studies did not get enough attention.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

1. female aging from 30 to 70-year old; 2. preoperative diagnosis of gynecologic malignancies; 3. have the ability to comply with Research programs; 4. voluntarily participate in the study and signed an informed consent form

Exclusion criteria

1. patients with severe cardiovascular diseases, kidney, liver and other vital organs diseases, bone marrow disease and mental illness; 2. patients suffering from autoimmune diseases; 3. patients with acute infectious disease or infection early phase of infection; 4. patients with urinary tract infection; 5. patients with infection or erosion of ano-genital skin; 6. for any other reason, the researchers considered unsuitable for inclusion.

Design outcomes

Primary

Measure	Time frame	Description
susceptibility genes localization	4 years	Based on high-throughput sequencing platform, we expect to screen out susceptibility genes location in PFD, providing theoretical basis for individualized prevention, intervention and treatment.

Countries

China

Outcome results